This site uses cookies to bring you the best experience. Find out more
Skip to main content

The Supplements

Medicines Development in Alzheimer's disease

The Graybook supplementary e-text on Medicines Development in Alzheimer´s disease is designed to provide a clear explanation of the basic facts how new medicines are tested in this field.

The sections are as follows:

  1. Foreword 
  2. Introduction
  3. Brain Basics
  4. Pathophysiology
  5. Symptoms
  6. Diagnostic criteria and tests
  7. Current treatments
  8. Symptomatic vs disease modifying approaches
  9. Regulatory Guidelines
  10. Clinical Trial Design and Phases
  11. Endpoints: clinical
  12. Endpoints: biochemical
  13. Endpoints:neuroimaging, other
  14. Key trial methodology issues
  15. Prevention studies
  16. Combination studies
  17. Appendix

The e-text is intended to be useful to anyone needing a concise summary about how new treatments for Alzheimer's disease are developed. While not a text on Alzheimer’s diseaseit6self, background information on the condition is included to the extent needed for understanding the corresponding development aspects. A short chapter on the basics of brain function has also been included for those new to this area.

The supplement is available at an additional cost to licensees of the Gray Book Standard or Professional version.